Cell damage and death releases alarmins, selfderived immunomodulatory molecules that recruit and activate the immune system. Unfortunately, numerous processes critical to the transplantation of allogeneic materials result in the destruction of donor and recipient cells and may trigger alarmin release. Alarmins, often described as damageassociated molecular patterns, together with exogenous pathogen-associated molecular patterns, are potent orchestrators of immune responses; however, the precise role that alarmins play in alloimmune responses remains relatively undefined. We examined evolving concepts regarding how alarmins affect solid organ and allogeneic hematopoietic cell transplantation outcomes and the mechanisms by which self molecules are released. We describe how, once released, alarmins may act alone or in conjunction with nonself materials to contribute to cytokine networks controlling alloimmune responses and their intensity. It is becoming recognized that this class of molecules has pleotropic functions, and certain alarmins can promote both inflammatory and regulatory responses in transplant models. Emerging evidence indicates that alarmins and their receptors may be promising transplantation biomarkers. Developing the therapeutic ability to support alarmin regulatory mechanisms and the predictive value of alarmin pathway biomarkers for early intervention may provide opportunities to benefit graft recipients.
Introduction
Transplant-associated procedures and alloimmune responses cause tissue and cell damage that can free endogenous (self-derived) molecules and exogenous (nonself) materials, which are perceived by the immune system. Pathogenassociated molecular patterns (PAMPs) found in nonself materials are recognized by pattern-recognition receptorsDr. Joost Oppenheim to define endogenous molecules that signal tissue and cell damage (4) . Although the impact of nonself material (viral, bacterial, or alloantigen) on solid organ transplantation (SOT) and transplant tolerance has been documented (6) (7) (8) , the way in which alloresponses are influenced by alarmins following transplantation has only recently begun to be considered. Likewise, how PAMPS and alarmins interface to direct transplant outcomes is poorly appreciated.
Alarmin Sources During Transplantation
Multiple processes involved in SOT, such as surgical procedures and associated ischemia-reperfusion injury (IRI) as well as recipient alloimmune responses, initiate a sterile inflammatory process that would not be associated with release of PAMPs (9) . Likewise, SOT and allogeneic hematopoietic cell transplantation (alloHCT) may use induction protocols containing irradiation or therapeutic agents that cause dramatic cell death in recipient tissues, particularly the epithelium (10) . Immunosuppressants and leukocytetargeting antibodies mediate the destruction of recipient leukocytes and other recipient cells. As such, numerous proposed alarmins would be expected to arise from damaged or dying host cells during transplantation. Although much attention has been placed on how PAMPs initiate the immune response, the way in which self molecules shape immune responses is only beginning to be uncovered. Suggested alarmins include several nuclear proteins, such as HMGB1, IL-1a, IL-33 and histones, and other cellular components such as mitochondria and mitochondrial DNA (11) , adenosine triphosphate (ATP), uric acid, HSPs, heme (12) , and haptoglobin (13) ( Table 1) . Multiple extracellular cellular matrix (ECM) fragments also have been suggested to act as alarmins, particularly heparan sulfate proteoglycan, fibronectin, fibrinogen, hyaluronate, biglycan, tenascin and hyaluronan. Details of many proposed alarmins (Table 1) have been provided in recent reviews, with several discussing the impact of alarmins on the alloimmune responses leading to graft-versus-host disease (GVHD) (10, 14, 15) . Rather than focusing on the general characterization of individual alarmins, we instead have discussed how an evolving understanding of alarmin immunobiology is being revealed in recent rodent studies, primarily examining the impact of HMGB1 or IL-33 on alloHCT and SOT.
Although alloHCT to generate mixed chimerism for the purpose of tolerance induction in SOT is not a new concept, the procedure has recently gained momentum. This procedure is still associated with greater incidence of early complications compared with traditional immunosuppression (16) , and GVHD remains a major potential complication following alloHCT (8, 17) . We took this opportunity to summarize new findings and historically important publications characterizing how alarmins modulate alloimmune responses after both alloHCT and SOT.
Alarmins as Proinflammatory Mediators After Transplantation
Alarmins were originally defined as proinflammatory endogenous molecules that mobilize and activate immune cells after cellular damage (4, 18) . A significant component of the proinflammatory capacity of alarmins has been attributed to the ability of many alarmins, including HMGB1, ATP and heme, to drive the stimulatory capacity of macrophages and dendritic cells (DCs) (19, 20) . Like PAMPs, alarmins can promote the production of proinflammatory cytokines, particularly the IL-12 family cytokines, IL-12p70 and IL-23. IL-12p70 signaling via IL-12Rb1 and IL-12Rb2 is key for development of CD4 + T helper cell type 1 (Th1) and directly promotes CD8 + T cell interferon c (IFN-c) production (21, 22) . In allotransplantation, IL-12 drives detrimental type 1 alloimmune responses by IFN-c + CD8 + T cells, which are critical for GVHD and implicated in acute and chronic heart transplant rejection and lost transplant tolerance. Likewise, IL-23 stabilizes Th17 cells, also implicated in GVHD and inferior SOT outcomes (21, 22 ).
An underappreciated capacity of IL-12p70 is its profound ability to synergize with IL-1 family members, including IL-1a, IL-b, IL-18, and IL-33, for the induction of IFN-c production by type 1 effector cells. IL-18 was initially identified and described as an IFN-c-inducing factor for its ability to enhance IFN-c production by T cells and natural killer (NK) cells, particularly in conjunction with IL-12 (23, 24) . The prototypical IL-1 family member IL-1b and the nuclear protein and alarmin IL-1a both promote IFN-c production by NK cells, albeit to a lesser degree than IL-18. Likewise, the IL-1 family member and classified alarmin IL-33 has emerged as a critical factor controlling type 1 cytokine production after transplantation. IL-33 is a nuclear protein upregulated under recipient inflammatory conditions and, once released, promotes detrimental type 1 donor alloimmunity and acute GVHD lethality (25) . Initially, this was surprising, given contrary evidence in other models that IL-33 is a potent mediator of type 2 and regulatory immune responses (26, 27) ; however, using donors deficient in IL-33R (also known as suppression of tumorigenicity 2 [ST2] and IL1RL1) and IL-33-deficient mice as well as IL-33 antagonists, we demonstrated that IL-33 released early after transplant drives type 1 immunity and lethal acute GVHD (25) . Interestingly, ST2 expression was necessary for upregulation of T cell IL-18R expression, and IL-12 is appreciated as a potent inducer of ST2 on CD8 + T cells (25, 28, 29) . Likewise, IL-1b can increase ST2 + on leukocytes, including myeloid antigen-presenting cells (APCs) (30) . Consequently, there is an amplification network involving alarmins, including the IL-1 alarmins, IL-1a and IL-33, other IL-1 cytokines, and IL-12 family members, that shape the proinflammatory environment after transplantation (Figure 1 ). Further work in transplant models is necessary to establish the precise relationships in this network and the ideal targets to limit alloimmunity. We demonstrated, for example, that the IL-33 antagonist soluble ST2 (sST2)-Fc given on days 0, 3, 6, and 9 after alloHCT was highly effective in preventing GVHD (25) .
Like IL-1a or IL-33, HMGB1 is a nuclear protein that acts as an alarmin when released from damaged or dying cells, contributing to the pathogenesis of various inflammatory diseases (31) . Similar to IL-1a, HMGB1 also turns myeloid APCs into potent T cell stimulators by upregulating APC costimulatory molecules and inducing proinflammatory cytokine secretion by APCs, particularly IL-12p70 (20) . As expected from these properties, released HMGB1 supports IRI (32, 33) and the alloimmune response leading to GVHD (34) and transplant rejection (35) (36) (37) (38) . Zou et al delivered anti-HMGB1 antibody to C57BL/6 recipients for 4 weeks after heterotopic transplantation of MHC class II disparate bm12 hearts and demonstrated that HMGB1 release supports chronic cardiac rejection (38) . Further assessments of heart allografts and sera both revealed increased HMGB1 levels after transplantation and decreased sera levels after anti-HMGB1 antibody delivery (38) . Mechanistic studies indicated that decreases in systemic HMGB1 result in less activated DCs and thus reduced Th1 and Th17 responses (38) . Li et al established that anti-HMGB1 antibodies suppressed B cell activation and reduced IFN-c and IL-17A production after xenotransplantation of rat hearts into BALB/c mice (36) . Anti-HMGB1 antibody delivery promoted allogeneic islet survival (39, 40) . Matsuoka et al found that HMGB1 triggered TLR2 and RAGE on monocytes to induce DC CD40 and IL-12 production, leading to islet rejection due to NK T cell (NKT cell) support of Gr-1 + CD11b
+ cell IFN-c production (40) . Treatment with antibody specific to IL-12 or CD40L could prevent early islet graft loss (40) . Similarly, anti-IL-6 antibody prevented HMGB1-induced NKT cell IFN-c production and ameliorated islet rejection (39) .
Experiments by Im et al revealed a profound increase in circulating HMGB1 and increased HMGB1 protein in the spleen of alloHCT mice during GVHD (34) . In addition, HMGB1 promoted alloreactive T cell proliferation ex vivo (34) . Interestingly, the indole-derived antioxidant NecroX-7 reduced target-tissue HMGB1 levels, stifled HMGB1-driven alloreactive T cell response ex vivo and decreased Th1 and Th17 generation in vivo after alloHCT (34) . NecroX-7 improved GVHD outcomes; this was ascribed to the capacity of NecroX-7 to reduce reactive oxygen species (ROS). The authors suggested that ROS supports HMGB1 translocation from the nucleus and subsequent release. It will be important, however, to further separate the impact of ROS reduction on HMGB1 directly because HMGB1 is inactivated in vivo by ROSinduced oxidation (41).
In total, there is accumulating evidence generated using anti-HMGB1 agents to support the conclusion that extracellular HMGB1 promotes heart and islet rejection via augmentation of IFN-c-and IL-17-dominated immune responses. Moving forward, it will be important to verify a direct detrimental role for HMGB1 in SOT and alloHCT using recently generated conditional knockout mice (42) . The use of the Cre-Lox system to target HMGB1 in GVHD target tissues or the allograft should be especially informative. The positive outcomes generated through the use of anti-HMGB1, anti-IL-6 or anti-IL-12 antibodies (39,40) suggest that blocking HMGB1 or disruption of the cytokine networks initiated by HMGB1 may be warranted in allotransplantation.
Alarmins Are Alarming but Not Necessarily Inflammatory
Notwithstanding the accumulating evidence that alarmins promote alloimmunity, as described earlier, there is a building consensus that some alarmins may be instrumental in stimulating tissue repair and immune regulation. Indeed, some alarmins appear poorly proinflammatory, especially in the absence of pathogens. Instead, they may primarily stimulate low-level local inflammation while orchestrating efforts to regulate local inflammatory responses and return the organism to homeostasis by mediating repair of damaged tissue repair (27, 29, (43) (44) (45) . In support of this view, multiple reports have demonstrated that preconditioning rodent recipients by systemic administration of alarmins, such as HMGB1 or IL-33, has a protective effect against IRI, can prolong survival in experimental transplant models and expands multiple regulatory cell populations including regulatory T cells (Tregs) and regulatory myeloid cells (26, 29, 46, 47) . HSP70 can + Tregs less responsive to IL-33. IL-12p70-stimulated T cells are resistant to regulation; however, in the absence of PAMPs, IL-33 does not cause DC proinflammatory cytokine production but instead stimulates them to secrete IL-2, which works with IL-33 to expand Treg populations, particularly the subset expressing ST2, which is both suppressive and implicated in tissue repair. APC, antigen-presenting cell; DC, dendritic cell; HMGB1, high-mobility group box 1; IFN-c, interferon c; NK, natural killer; PAMPs, pathogenassociated molecular patterns; ST2, suppression of tumorigenicity 2; Th, T helper cell; TLR, Toll-like receptor; Treg, regulatory T cell. also mediate protective functions against ischemic kidney injury through modulation of Tregs (48). Hyaluronan, a major ECM component, is a nonsulfated glycosaminoglycan that exists as an extremely high-molecular-weight polymer (>4000 KDa) under normal physiological conditions (49, 50) . During tissue injury and local inflammation, including lung transplant rejection, hyaluronan is degraded to a lower molecular weight hyaluronan species (100-400 KDa) that activates DCs and macrophages via TLR2 and TLR4 (50) (51) (52) . Accumulated lower molecular weight hyaluronan species are potent stimulators of inflammation after lung injury and drive lung transplant rejection, especially if they can not be removed via the lymphatic vessels (50, 52) . Nevertheless, consistent with the dual roles displayed by other alarmins in inflammation and its resolution, the presence of high-molecular-weight hyaluronan supports lung epithelial cell integrity (51) and attenuates allograft inflammation (53) .
High doses of many alarmins stimulate immune cell production of proinflammatory cytokines, including IL-1b, IL-6, IL-12p70, and IL-23, and facilitate type 1 immunity (12, 13, 15, 20) ; however, alarmin release that is part of normal cell turnover must not reach a level required to sustain a proinflammatory environment. We found that IL-33 alone does not induce significant DC secretion of IL-1b, IL-6, IL-12p70, or IL-23 and does not support DC generation of allogeneic Th1 or Th17 responses (29) . Instead, IL-33 endows DCs with the capacity for Th2 polarization and Treg expansion (29) . The capacity of IL-33 to expand Tregs is due, at least in part, to its capacity to stimulate DC and mast cell secretion of IL-2 (29, 54) Interestingly, although IL-33 does not induce significant macrophage proinflammatory cytokine production, it does not impede and actually augments IL-6 secretion on subsequent exposure to lipopolysaccharide (55) . During tissue damage, although released IL-33 would not stimulate, it also would not be expected to limit DC activation by PAMPs derived from infiltrating pathogens. DC response to PAMPs is typified by IL-12p70 secretion leading to ST2 upregulation on CD8 + T cells (25, 28) . ST2 expression allows CD8 + T cells to respond to IL-33 and TCR stimulation with profoundly augmented IFN-c production (25, 28, 29) . IL-12p70, IL-1b, IL-6, and IL-23 are also commonly produced by PAMP-stimulated myeloid cells. In addition to promoting type 1 and Th17 immune responses, these cytokines each have been demonstrated to limit Treg functions (56) . Consequently, PAMPactivated DCs may propagate proinflammatory states by secreting cytokines that differentiate T effectors, but that also counter the function of Tregs expanding in response to alarmins.
We suggest that the local presence of other proinflammatory cytokines is a critical switch controlling alarmin regulatory versus proinflammatory functions. IL-12, for example, has been shown to support effector T cell proliferation and cytokine production even in the presence of Tregs (22) . Similarly, IL-23 negatively regulates the differentiation of CD4 + T cells into Tregs (22) + Treg responses to IL-33 and drive Th17 immunity (Figure 1) . Likewise, IL-12p70-induced expression of ST2 on CD8 + T cells would switch IL-33 functions toward those supporting pathogen removal via CD8 and CD4 production of IFN-c (Figure 1 ). Such mechanisms, although logical, need to be tested directly. Initial studies in mice using an anti-IL-12p40 antibody that targets the shared subunit of both IL-12 and IL-23 have been promising. These studies found anti-IL-12p40 antibodies reduced Th1 and Th17 T cell polarization in vivo during GVHD (57, 58) and following heart allograft transplantation in mice (59,60). There was little or no impact on Th2 or Treg populations. This suggests that countering IL-12 and IL-23 in vivo will limit the proinflammatory functions of certain alarmins, thereby permitting the regulatory and/or tissue reparative pathways to prevail. Although most of these studies have focused on the outcome of T cell polarization, further experiments that identify mechanisms underlying these effects are needed to fully understand how to successfully manipulate these cytokine pathways for the benefit of transplantation outcome.
Mechanisms of Alarmin Release and Their Relationship to Proinflammation
Recipient conditioning, as well as donor organ IRI and posttransplant antialloimmune responses, results in cell death and tissue damage that provides a source of released alarmins and potentially accompanying alloantigens. Although much still needs to be understood regarding how the simultaneous release of intracellular alarmins and alloantigen from dying cells affects alloimmune responses and transplant outcomes, recent publications suggest the importance of this knowledge. In the case of alloHCT, the rapidly dividing cells of mucosal barrier tissues are particularly susceptible to death during conditioning regimens. Barrier tissue breaches result in the release of commensal bacteria-associated PAMPs that instigate proinflammatory cytokine generation supporting GVHD development. A growing body of evidence also has implicated PAMP signaling in several regulated cell death (RCD) pathways (61) . Apoptosis is a common RCD pathway that involves the apoptotic caspases 3, 7 and 8 and is viewed as noninflammatory cell death (61) . Necroptosis, however, is caspase independent and requires receptor-interacting protein kinase 3 (RIP3K) activity (61) . Unlike apoptosis, which is regarded as a noninflammatory mechanism of cell death, necroptosis and other nonapoptotic RCD pathways (e.g. ferroptosis or pyroptosis) result in membrane rupture and release of cell contents such that they trigger an inflammatory response (61) . A detrimental impact of alarmins released by necroptosis after heart transplant has been suggested in rodents (62) . Interestingly, PAMP signaling also increases cellular alarmin levels (63, 64) . Consequently, PAMP-driven signaling could both increase expression of these potential proinflammatory mediators while facilitating their release into the extracellular space by triggering RCD. This may be a particularly important pathway for nuclear alarmins, including IL-33 and HMGB1, to exit the cell in an inflammatory context and may contribute to systemic immune responses. Once released, IL-33 can be subjected to proteolytic cleavage by neutrophil elastases that enhance its bioactivity (65) . The fact that neutrophils are typically the first responders following gut tissue injury suggests that neutrophil elastase cleavage of IL-33 may be a significant mechanism supporting inflammation (65).
Interesting work assessing how dying cells initiate adaptive immunity indicates that alarmins are not inherently able to promote adaptive immunity (66) . In fact, the release of HMGB1 and ATP from a dying cell alone could not promote robust cross-priming and CD8 responses to released antigens unless nuclear factor jB and RIP1K were also activated in dying cells. Moving forward, it can be expected that the study of how RCD, especially of alloantigen-expressing graft cells, shapes alarmin function and alloimmune responses will be a critical area of research in transplantation.
Alarmins and Their Receptors as Diagnostic and Prognostic Biomarkers
Biomarkers that can readily identify pathogenic alloimmune response are needed to improve outcomes after both SOT and alloHCT. Because alarmin expression is often driven by local inflammation or proinflammatory cytokines, alarmins may have the potential to act as sensitive transplant biomarkers. Serum levels of HMGB1 and the heme binding protein haptoglobin are indicative of solid organ damage (13, 67) and GVHD (68, 69) . Although IL-33 serum levels increase during numerous inflammatory diseases (70) , there are no reports that serum IL-33 is meaningfully increased during alloimmune responses. Conversely, several examples now suggest that measuring serum levels of the IL-33 antagonist sST2 may have value in transplantation. sST2 is an IL-33 decoy receptor generated through alternative RNA splicing and processing of the same RNA that also yields ST2, the membrane-bound signaling form (71, 72) . ST2 and sST2 are induced or augmented in leukocytes and stromal cells by proinflammatory cytokines, TLR ligands and mechanical stress. Building on our early rodent studies that established that ST2 is increased locally but not systemically during rejection of heterotopic heart transplants (26), we showed that the alloimmune-associated proinflammatory cytokines increase graft ST2 during rejection episodes in pediatric SOT recipients (73) . Graft ST2 increases were reflected in increased serum sST2 levels that signified rejection in cohorts of small bowel or heart transplant recipients (73) . Similarly, high serum sST2 acts as a reliable biomarker predicting resistance in GVHD patients to corticosteroid therapy and nonrelapse mortality (74) . Additional studies found high sST2 levels at day 28 after transplant with increased transplant-related mortality and acute GVHD (75) . Further supporting the value of ST2 monitoring after alloHCT was the report that ST2, with TNFR1 and Reg3a, could classify patients at GVHD onset into those at risk of treatment failure and nonrelapse mortality (76) . In total, these studies suggest that routine serum sST2 quantification, especially combined with other biomarkers, will have value in supporting biopsy-free detection of early allograft rejection in SOT and aid effective therapeutic resolution of alloimmune responses causing graft rejection or GVHD.
Conclusions
The study of alarmins and their influence on alloimmune responses suggests that how cells die and the way they release both these potentially immunostimulatory contents and alloantigens is of critical importance to alloHCT and SOT outcomes. Mounting evidence from transplant and other disease and infection models shows that alarmins can be both inflammatory and regulatory. Such observations suggest that developing an understanding of the processes that control alarmin functions may allow us to harness alarmins by countering their proinflammatory triggers and optimizing their regulatory properties.
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